stockrowVeracyte, Inc.
VCYT Healthcare Diagnostics & Research
Veracyte, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $517.1 million, up 16.0% from fiscal 2024.
- Revenue
- +15.1%
- EPS
- +62.5%
- Free cash flow
- −9.63%
Quarter to September 2026, against a year earlier
Follow VCYT
Alert me
Veracyte, Inc. (VCYT) Gross margin
Veracyte, Inc.'s gross margin over the twelve months to 30 September 2026 was 72.0%, up 1.9 percentage points from fiscal 2025 (70.1%). Over the past ten years it has ranged from 56.6% (fiscal 2015) to 70.1% (fiscal 2025) — the current reading is the highest in ten years. That is above the Diagnostics & Research industry median of 48.3% and above the Healthcare sector median of 53.9%.
Gross margin, annual
Embed this chart
Annual newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2025 | 70.1% | 3.22 |
| FY2024 | 66.9% | 3.26 |
| FY2023 | 63.6% | 4.38 |
| FY2022 | 59.2% | (6.87) |
| FY2021 | 66.1% | 1.40 |
| FY2020 | 64.7% | (4.95) |
| FY2019 | 69.7% | 5.61 |
| FY2018 | 64.1% | 3.24 |
| FY2017 | 60.8% | (0.07) |
| FY2016 | 60.9% | 4.31 |
Quarterly newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| Sep 2026 | 70.6% | (1.63) |
| Jun 2026 | 72.2% | (0.53) |
| Mar 2026 | 72.7% | 0.23 |
| Dec 2025 | 72.5% | 3.29 |
| 43 more quarters | Free account |
Against its own ten years
Gross margin against peers
| Company | Gross margin |
|---|---|
| ADPT Adaptive Biotechnologies Corporation compare | 74.2% |
| VCYT Veracyte, Inc. | 72.0% |
| BLLN BillionToOne, Inc. compare | 71.4% |
| CDNA CareDx, Inc. compare | 71.0% |
| WGS GeneDx Holdings Corp. compare | 69.4% |
| SHC Sotera Health Company compare | 54.6% |
| NEO NeoGenomics, Inc. compare | 44.8% |
| RDNT RadNet, Inc. compare | 11.5% |
| GRAL GRAIL, Inc. compare | 0.00% |
| Diagnostics & Research industry median | 48.3% |
| Healthcare sector median | 53.9% |
| Market median | 45.1% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue
More on VCYT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement